INHIBITION OF HIV IN-VITRO BY ANTIVIRAL DRUG-TARGETING USING NANOPARTICLES

被引:48
作者
BENDER, A
SCHAFER, V
STEFFAN, AM
ROYER, C
KREUTER, J
RUBSAMENWAIGMANN, H
VONBRIESEN, H
机构
[1] UNIV FRANKFURT,INST PHARMAZEUT TECHNOL,D-60053 FRANKFURT,GERMANY
[2] GEORG SPEYER HAUS,CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY
[3] UNIV STRASBOURG 1,VIROL LAB,F-67000 STRASBOURG,FRANCE
来源
RESEARCH IN VIROLOGY | 1994年 / 145卷 / 3-4期
关键词
HIV; NANOPARTICLE; MICROSPHERE; ANTIVIRAL AGENT; MACROPHAGE; DRUG-TARGETING;
D O I
10.1016/S0923-2516(07)80025-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nanoparticles are known to accumulate in the phagocytic cells of the mononuclear phagocyte system. Therefore, the use of this carrier system for the targeting of antiviral drugs to monocytes/macrophages (MO/MAC) is an attractive concept in the treatment of diseases involving MO/MAC, e.g. infection with HIV. In this study, the ability of macrophages isolated from peripheral blood of healthy blood donors to phagocytose and metabolize human serum albumin microspheres was investigated by transmission electron microscopy. Furthermore, nanoparticles manufactured using human serum albumin or polyhexylcyanoacrylate were loaded with nucleoside analogues (AZT and ddC) and tested for their ability to prevent HIV infection in MO/MAC cultures. Our results demonstrate the effectiveness of this drug-targeting system to one of the major target cells for HIV.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 19 条
[1]   PRIMARY CULTURES OF HUMAN BLOOD-BORNE MACROPHAGES GROWN ON HYDROPHOBIC TEFLON MEMBRANES [J].
ANDREESEN, R ;
PICHT, J ;
LOHR, GW .
JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 56 (03) :295-304
[2]  
Couvreur P, 1982, US patent, Patent No. [4329332 A, 4329332]
[3]   DRUG TARGETING WITH POLYALKYLCYANOACRYLATE NANOPARTICLES - INVITRO ACTIVITY OF PRIMAQUINE-LOADED NANOPARTICLES AGAINST INTRACELLULAR LEISHMANIA-DONOVANI [J].
GASPAR, R ;
OPPERDOES, FR ;
PREAT, V ;
ROLAND, M .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1992, 86 (01) :41-49
[4]  
KREUTER J, 1983, PHARM ACTA HELV, V58, P196
[5]  
KREUTER J, 1979, J PHARM SCI, V68, P1444
[6]   PATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
LEVY, JA .
MICROBIOLOGICAL REVIEWS, 1993, 57 (01) :183-289
[7]  
MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
[8]   MACROPHAGES AND THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].
MELTZER, MS ;
SKILLMAN, DR ;
HOOVER, DL ;
HANSON, BD ;
TURPIN, JA ;
KALTER, DC ;
GENDELMAN, HE .
IMMUNOLOGY TODAY, 1990, 11 (06) :217-223
[9]  
PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
[10]  
ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162